Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
Innovation & Entrepreneurship
Strategy / MBA Resources
Case Study SWOT Analysis Solution
Case Study Description of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery
This case explores the difficulties involved in commercialising vaccines in low-income settings. The focus is the dengue vaccine, launched at the end of 2015, which was first commercialised in emerging markets. It considers issues of affordability and distribution, higlighting the need for business model innovation in all industries.
Swot Analysis of "Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery" written by Philip Parker, Pierfitte Marion includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Vaccine Dengue facing as an external strategic factors. Some of the topics covered in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study are - Strategic Management Strategies, Emerging markets, Health and Innovation & Entrepreneurship.
Some of the macro environment factors that can be used to understand the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery casestudy better are - – banking and financial system is disrupted by Bitcoin and other crypto currencies, supply chains are disrupted by pandemic , cloud computing is disrupting traditional business models, increasing inequality as vast percentage of new income is going to the top 1%, there is backlash against globalization, central banks are concerned over increasing inflation, increasing household debt because of falling income levels,
increasing energy prices, there is increasing trade war between United States & China, etc
Introduction to SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Vaccine Dengue, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Vaccine Dengue operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery can be done for the following purposes –
1. Strategic planning using facts provided in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study
2. Improving business portfolio management of Vaccine Dengue
3. Assessing feasibility of the new initiative in Innovation & Entrepreneurship field.
4. Making a Innovation & Entrepreneurship topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Vaccine Dengue
Strengths Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Vaccine Dengue in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Harvard Business Review case study are -
Digital Transformation in Innovation & Entrepreneurship segment
- digital transformation varies from industry to industry. For Vaccine Dengue digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Vaccine Dengue has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Ability to lead change in Innovation & Entrepreneurship field
– Vaccine Dengue is one of the leading players in its industry. Over the years it has not only transformed the business landscape in its segment but also across the whole industry. The ability to lead change has enabled Vaccine Dengue in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Analytics focus
– Vaccine Dengue is putting a lot of focus on utilizing the power of analytics in business decision making. This has put it among the leading players in the industry. The technology infrastructure suggested by Philip Parker, Pierfitte Marion can also help it to harness the power of analytics for – marketing optimization, demand forecasting, customer relationship management, inventory management, information sharing across the value chain etc.
Cross disciplinary teams
– Horizontal connected teams at the Vaccine Dengue are driving operational speed, building greater agility, and keeping the organization nimble to compete with new competitors. It helps are organization to ideate new ideas, and execute them swiftly in the marketplace.
Sustainable margins compare to other players in Innovation & Entrepreneurship industry
– Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery firm has clearly differentiated products in the market place. This has enabled Vaccine Dengue to fetch slight price premium compare to the competitors in the Innovation & Entrepreneurship industry. The sustainable margins have also helped Vaccine Dengue to invest into research and development (R&D) and innovation.
Ability to recruit top talent
– Vaccine Dengue is one of the leading recruiters in the industry. Managers in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are in a position to attract the best talent available. The firm has a robust talent identification program that helps in identifying the brightest.
Successful track record of launching new products
– Vaccine Dengue has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Vaccine Dengue has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
Training and development
– Vaccine Dengue has one of the best training and development program in the industry. The effectiveness of the training programs can be measured in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Harvard Business Review case study by analyzing – employees retention, in-house promotion, loyalty, new venture initiation, lack of conflict, and high level of both employees and customer engagement.
Effective Research and Development (R&D)
– Vaccine Dengue has innovation driven culture where significant part of the revenues are spent on the research and development activities. This has resulted in, as mentioned in case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery - staying ahead in the industry in terms of – new product launches, superior customer experience, highly competitive pricing strategies, and great returns to the shareholders.
Diverse revenue streams
– Vaccine Dengue is present in almost all the verticals within the industry. This has provided firm in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study a diverse revenue stream that has helped it to survive disruptions such as global pandemic in Covid-19, financial disruption of 2008, and supply chain disruption of 2021.
Highly skilled collaborators
– Vaccine Dengue has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive segment. Secondly the value chain collaborators of the firm in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery HBR case study have helped the firm to develop new products and bring them quickly to the marketplace.
Strong track record of project management
– Vaccine Dengue is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Weaknesses Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are -
High bargaining power of channel partners
– Because of the regulatory requirements, Philip Parker, Pierfitte Marion suggests that, Vaccine Dengue is facing high bargaining power of the channel partners. So far it has not able to streamline the operations to reduce the bargaining power of the value chain partners in the industry.
Slow to harness new channels of communication
– Even though competitors are using new communication channels such as Instagram, Tiktok, and Snap, Vaccine Dengue is slow explore the new channels of communication. These new channels of communication mentioned in marketing section of case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery can help to provide better information regarding products and services. It can also build an online community to further reach out to potential customers.
High operating costs
– Compare to the competitors, firm in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery has high operating costs in the. This can be harder to sustain given the new emerging competition from nimble players who are using technology to attract Vaccine Dengue 's lucrative customers.
Capital Spending Reduction
– Even during the low interest decade, Vaccine Dengue has not been able to do capital spending to the tune of the competition. This has resulted into fewer innovations and company facing stiff competition from both existing competitors and new entrants who are disrupting the industry using digital technology.
Aligning sales with marketing
– It come across in the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery that the firm needs to have more collaboration between its sales team and marketing team. Sales professionals in the industry have deep experience in developing customer relationships. Marketing department in the case Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery can leverage the sales team experience to cultivate customer relationships as Vaccine Dengue is planning to shift buying processes online.
Skills based hiring
– The stress on hiring functional specialists at Vaccine Dengue has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Vaccine Dengue supply chain. Even after few cautionary changes mentioned in the HBR case study - Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, it is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Vaccine Dengue vulnerable to further global disruptions in South East Asia.
Workers concerns about automation
– As automation is fast increasing in the segment, Vaccine Dengue needs to come up with a strategy to reduce the workers concern regarding automation. Without a clear strategy, it could lead to disruption and uncertainty within the organization.
Compensation and incentives
– The revenue per employee as mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, is just above the industry average. Vaccine Dengue needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
Need for greater diversity
– Vaccine Dengue has taken concrete steps on diversity, equity, and inclusion. But the efforts so far has resulted in limited success. It needs to expand the recruitment and selection process to hire more people from the minorities and underprivileged background.
Employees’ incomplete understanding of strategy
– From the instances in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, it seems that the employees of Vaccine Dengue don’t have comprehensive understanding of the firm’s strategy. This is reflected in number of promotional campaigns over the last few years that had mixed messaging and competing priorities. Some of the strategic activities and services promoted in the promotional campaigns were not consistent with the organization’s strategy.
Opportunities Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are -
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Vaccine Dengue can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Vaccine Dengue in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the Innovation & Entrepreneurship segment, and it will provide faster access to the consumers.
Creating value in data economy
– The success of analytics program of Vaccine Dengue has opened avenues for new revenue streams for the organization in the industry. This can help Vaccine Dengue to build a more holistic ecosystem as suggested in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study. Vaccine Dengue can build new products and services such as - data insight services, data privacy related products, data based consulting services, etc.
Finding new ways to collaborate
– Covid-19 has not only transformed business models of companies in Innovation & Entrepreneurship industry, but it has also influenced the consumer preferences. Vaccine Dengue can tie-up with other value chain partners to explore new opportunities regarding meeting customer demands and building a rewarding and engaging relationship.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Vaccine Dengue can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help, as suggested in case study, Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Vaccine Dengue is facing challenges because of the dominance of functional experts in the organization. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery case study suggests that firm can utilize new technology to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Vaccine Dengue can use these opportunities to build new business models that can help the communities that Vaccine Dengue operates in. Secondly it can use opportunities from government spending in Innovation & Entrepreneurship sector.
Using analytics as competitive advantage
– Vaccine Dengue has spent a significant amount of money and effort to integrate analytics and machine learning into its operations in the sector. This continuous investment in analytics has enabled, as illustrated in the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery - to build a competitive advantage using analytics. The analytics driven competitive advantage can help Vaccine Dengue to build faster Go To Market strategies, better consumer insights, developing relevant product features, and building a highly efficient supply chain.
Learning at scale
– Online learning technologies has now opened space for Vaccine Dengue to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Low interest rates
– Even though inflation is raising its head in most developed economies, Vaccine Dengue can still utilize the low interest rates to borrow money for capital investment. Secondly it can also use the increase of government spending in infrastructure projects to get new business.
Better consumer reach
– The expansion of the 5G network will help Vaccine Dengue to increase its market reach. Vaccine Dengue will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Remote work and new talent hiring opportunities
– The widespread usage of remote working technologies during Covid-19 has opened opportunities for Vaccine Dengue to expand its talent hiring zone. According to McKinsey Global Institute, 20% of the high end workforce in fields such as finance, information technology, can continously work from remote local post Covid-19. This presents a really great opportunity for Vaccine Dengue to hire the very best people irrespective of their geographical location.
Loyalty marketing
– Vaccine Dengue has focused on building a highly responsive customer relationship management platform. This platform is built on in-house data and driven by analytics and artificial intelligence. The customer analytics can help the organization to fine tune its loyalty marketing efforts, increase the wallet share of the organization, reduce wastage on mainstream advertising spending, build better pricing strategies using personalization, etc.
Threats Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery are -
Barriers of entry lowering
– As technology is more democratized, the barriers to entry in the industry are lowering. It can presents Vaccine Dengue with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Vaccine Dengue needs to understand the core reasons impacting the Innovation & Entrepreneurship industry. This will help it in building a better workplace.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Vaccine Dengue can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate prominent markets illustrated in HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery .
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Consumer confidence and its impact on Vaccine Dengue demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in the industry and other sectors.
Stagnating economy with rate increase
– Vaccine Dengue can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
Instability in the European markets
– European Union markets are facing three big challenges post Covid – expanded balance sheets, Brexit related business disruption, and aggressive Russia looking to distract the existing security mechanism. Vaccine Dengue will face different problems in different parts of Europe. For example it will face inflationary pressures in UK, France, and Germany, balance sheet expansion and demand challenges in Southern European countries, and geopolitical instability in the Eastern Europe.
Technology acceleration in Forth Industrial Revolution
– Vaccine Dengue has witnessed rapid integration of technology during Covid-19 in the Innovation & Entrepreneurship industry. As one of the leading players in the industry, Vaccine Dengue needs to keep up with the evolution of technology in the Innovation & Entrepreneurship sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Vaccine Dengue in the Innovation & Entrepreneurship sector and impact the bottomline of the organization.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Vaccine Dengue in the Innovation & Entrepreneurship industry. The Innovation & Entrepreneurship industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, as highlighted in case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery, Vaccine Dengue may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of Innovation & Entrepreneurship .
High dependence on third party suppliers
– Vaccine Dengue high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Regulatory challenges
– Vaccine Dengue needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Innovation & Entrepreneurship industry regulations.
Weighted SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Vaccine Dengue needs to make to build a sustainable competitive advantage.
Feel free to connect with us if you need business research.
You can download Excel Template of Case Study Solution & Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (B): Business Model Innovation in Vaccine Delivery
